Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Forster

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Cancer Research|May 17, 2008
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945Radhakrishna G Pillai, Martin Forster, Meg Perumal, et al.
The Lancet. Oncology|August 1, 2016
Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trialAhmed A Sultan, Waseem Jerjes, Kristian Berg, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
Cancers|July 29, 2025
Oxygen-Enhanced R2* Weighted MRI and Diffusion Weighted MRI of Head and Neck Squamous Cell Cancer Lymph Nodes in Prediction of 2-Year Outcome Following ChemoradiotherapyHarbir Singh Sidhu, David Price, Tim Beale, et al.
Blood|July 9, 2009
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2CMaike Schwieger, Andrea Schüler, Martin Forster, et al.
NMR in Biomedicine|July 9, 2021
Utility of diffusion MRI characteristics of cervical lymph nodes as disease classifier between patients with head and neck squamous cell carcinoma and healthy volunteersMarianthi-Vasiliki Papoutsaki, Harbir Singh Sidhu, Nikolaos Dikaios, et al.
JTO Clinical and Research Reports|October 15, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyMatthew G Krebs, Martin Forster, Margarita Majem, et al.
Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib TrialDean A Fennell, Sarah Danson, Penella J Woll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell CarcinomaMartin Forster, Irene Brana, Antonio L Pousa, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Cancer Research|May 17, 2008
Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945Radhakrishna G Pillai, Martin Forster, Meg Perumal, et al.
The Lancet. Oncology|August 1, 2016
Disulfonated tetraphenyl chlorin (TPCS2a)-induced photochemical internalisation of bleomycin in patients with solid malignancies: a phase 1, dose-escalation, first-in-man trialAhmed A Sultan, Waseem Jerjes, Kristian Berg, et al.
Clinical Colorectal Cancer|November 9, 2018
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center ExperienceKhurum Khan, Jayant K Rane, David Cunningham, et al.
Cancers|July 29, 2025
Oxygen-Enhanced R2* Weighted MRI and Diffusion Weighted MRI of Head and Neck Squamous Cell Cancer Lymph Nodes in Prediction of 2-Year Outcome Following ChemoradiotherapyHarbir Singh Sidhu, David Price, Tim Beale, et al.
Blood|July 9, 2009
Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2CMaike Schwieger, Andrea Schüler, Martin Forster, et al.
NMR in Biomedicine|July 9, 2021
Utility of diffusion MRI characteristics of cervical lymph nodes as disease classifier between patients with head and neck squamous cell carcinoma and healthy volunteersMarianthi-Vasiliki Papoutsaki, Harbir Singh Sidhu, Nikolaos Dikaios, et al.
JTO Clinical and Research Reports|October 15, 2024
Eftilagimod Alpha (a Soluble LAG-3 Protein) Combined With Pembrolizumab in Second-Line Metastatic NSCLC Refractory to Anti-Programmed Cell Death Protein 1/Programmed Death-Ligand 1-Based Therapy: Final Results from a Phase 2 StudyMatthew G Krebs, Martin Forster, Margarita Majem, et al.
Investigational New Drugs|November 23, 2016
Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumorsLuis Paz-Ares, Martin Forster, Valentina Boni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2020
Ganetespib in Combination with Pemetrexed-Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib TrialDean A Fennell, Sarah Danson, Penella J Woll, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
Eftilagimod Alpha (Soluble LAG3 Protein) Combined with Pembrolizumab as Second-Line Therapy for Patients with Metastatic Head and Neck Squamous Cell CarcinomaMartin Forster, Irene Brana, Antonio L Pousa, et al.
Pageof 9